...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: This so called “Expert Market”

Fuzzy I agree this looks like another Eversana type deal, albeit with a much larger organization.  On the IP side Zen 3694 seems to be doing quite well with all the trials that are moving along but hopefully this is not another case of management exercising its' usual poor judgement, getting the cart before the horse again and spending money they don't have.  It truly is shameful to have all this potential not performing for investors because "leadership" is not competent.  At the RVX meeting Don said there was all kinds of money out there attached to failed technology so where are the business deals?  I guess still waiting for a real CEO.  

Perhaps this deal is a precursor to getting a royalty deal done, and to me it does make sense for someone to want a Zen3694 royalty, but managements 20+ year track record of selling zero pure royalty or licensing deals doesn't leave me feeling confident.  So much for Don's past assessment that while a cardiovascular program can take 20 years most cancer programs can be completed and sold in about 8 years.

Calgary alone is awash in investment capital (my kid who is a corporate lawyer tells me every month they're involved in papering investment deals involving multiple investors who all have net worths of $50-100 million+).  The fact that Don has a brother who is familiar with those circles (Bill, who I've always assumed is the "relative of the CEO", was the founder of MEG Energy - MEG was originally McCaffrey Energy Group) yet RVX/Zenith can't access deals there, despite very promising IP, to me speaks volumes of the local market confidence in management.

Last year I asked when Don felt that Zenith Capital might be showing investors some return.  He said he thought in about a year.  When I then reviewed the list of trials I thought perhaps he might be lining up a sale of at least Zen3694. My mistake.  With yesterday's pr a sale seems highly unlikely and highly unlikely investors will be shown any return near term.  More than very disappointing.

I'm a little cynical on the timing of this announcement as it just comes across as a cheap trick to divert attention from the fact that once again very little has really been accomplished in terms of moving the company forward from a business perspective.

I was thinking of going to the AGM today but if it's just going to be Don all excited about Cencora and also giving us his grade 12 science presentation on the IP then I can likely find something better to do with my time. I think most of us want to hear about some real business progress and how we are going to actually make some money on this investment.

Share
New Message
Please login to post a reply